Most direct‐acting antivirals (DAAs) that are being developed as therapy against hepatitis C
virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter …

The current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition
of direct‐acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the …

Background. Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis
C virus (HCV) in the majority of treatment-naive patients. DAAs for HCV infection have …

Background: Chronic hepatitis C virus (HCV) infection causes a substantial health and
economic burden in the United States. With the availability of direct-acting antiviral agents …

Background & Aims Hepatitis C (HCV) is a common cause of chronic liver disease
worldwide. Current standard treatment for genotype-1 patients uses a triple combination of …

Present interferon‐based therapy for chronic hepatitis C is limited by both efficacy and
tolerability. Telaprevir and boceprevir are the first two direct‐acting antiviral drugs (DAAs) …

Prominent in the current stage of antiviral drug development are:(i) for human
immunodeficiency virus (HIV), the use of fixed‐dose combinations (FDCs), the most recent …

Abstract The HCV RNA-dependent RNA polymerase is an essential enzyme in HCV viral
replication and has been a prominent target in the search for therapies to treat individuals …

Chronic infection with hepatitis C virus (HCV) is a major global health problem; there are
approximately 120 to 130 million chronic infections worldwide. Since the discovery of HCV …

Two direct-acting antivirals (DAAs) against hepatitis C virus (HCV): telaprevir and
boceprevir, are now available in combination with peginterferon plus ribavirin for the …